“TS,S/AS01E was first introduced within the Malaria Vaccine Implementation Programme in selected areas in Ghana, Kenya, and Malawi. A series of post-introduction observational studies were initiated in these areas to assess RTS,S/AS01E safety and effectiveness in real-world settings. Here, we report the results of the interim analysis of the EPI-MAL-003 study secondary objectives related to vaccine effectiveness…

Over 12 months after the third RTS,S/AS01E dose, country-adjusted IRRs suggest a 30% reduction in any malaria and a 58% reduction in severe malaria. No cerebral malaria occurred in the vaccinated children over the follow-up period”

From The Lancet.